An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Mepsevii

Chemical Namevestronidase alfa
Dosage FormInjection (intravenous; 10 mg/5 mL)
Drug ClassEnzymes
SystemNervous, Digestive, Musculoskeletal, Endocrine
CompanyUltragenyx Pharm Inc
Approval Year2017

Indication

  • To treat pediatric and adult patients with an inherited metabolic condition called mucopolysaccharidosis type VII (MPS VII), also known as Sly syndrome.
Last updated on 10/9/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Mepsevii (vestronidase alfa) Prescribing Information2019Ultragenyx Pharmaceutical Inc.
Document TitleYearSource
A study of UX003 recombinant human beta-glucuronidase (rhGUS) enzyme replacement therapy in subjects with mucopolysaccharidosis type 7, Sly syndrome (MPS 7)2020Ultragenyx Pharmaceutical Inc.
Pharmacokinetic and pharmacodynamic modeling to optimize the dose of vestronidase alfa, an enzyme replacement therapy for treatment of patients with mucopolysaccharidosis type VII: results from three trials2019Clinical Pharmacokinetics